-
07:25:37 PM

ARQT Stock News

03/09/23 8:00 AM
Nasdaq : ARQT
conferenceshigh short
Arcutis to Present New Topical Roflumilast Data Including Late Breaking Atopic Dermatitis Pivotal Trial Data During the American Academy of Dermatology (AAD) Annual Meeting
Late breaking session to highlight new data from the INTEGUMENT Phase 3 trials evaluating roflumilast cream in atopic dermatitis New national survey insights depicting disease burden, path to diagnosis and treatment patterns for seborrheic dermatitis New clinical safety and efficacy data of topical
RHEA-AI
neutral
01/14/23 4:00 AM
Nasdaq : ARQT
clinical trialhigh short
Arcutis Presents New Phase 2 Long-Term Data Showing Sustained Efficacy and Clearance for a Median of 10 Months with Roflumilast Cream in Adults with Chronic Plaque Psoriasis
During the open label trial, 57.1% of roflumilast-treated participants achieved Investigator Global Assessment (IGA) of clear or almost clear at any time in study; the median duration of clear or almost clear was 10 months (40.1 weeks) Efficacy was consistent over time across all endpoints, and no
RHEA-AI
positive
12/19/22 8:00 AM
Nasdaq : ARQT
high short
Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% for Expanded Indication for the Treatment of Plaque Psoriasis in Children Down to 2 Years of Age
Regulatory submission for the expanded indication is supported by data from two recently completed 4-week Maximal Usage Systemic Exposure (MUSE) studies in children ages 2 to 11 years with plaque psoriasis If approved, ZORYVE would be the first steroid-free topical phosphodiesterase-4 (PDE4)
RHEA-AI
neutral